OXB Named Among UK’s Best Employers by Financial Times in 2025

OXB Named Among UK’s Best Employers by Financial Times in 2025

Oxford, UK – OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the Financial Times’ prestigious ‘UK Best Employers 2025’ list. This recognition underscores OXB’s commitment to excellence and innovation in its corporate culture.

The Financial Times' UK Best Employers list is compiled annually through a rigorous process that involves a detailed analysis of company practices, employee surveys, and external data from hundreds of companies across the UK. Criteria such as workplace diversity, career development opportunities, and employee satisfaction are meticulously assessed to determine the leaders in corporate excellence.

"We are thrilled to be recognised by the Financial Times as one of the UK’s best employers," said Julie Copperthwaite, Head of Group HR Operations at OXB. "This distinction is a testament to our dedicated team who are not only passionate about driving scientific innovation but are also committed to creating an inclusive and supportive work environment."

This recognition from the Financial Times highlights OXB’s role as a leader not only in the field of biotechnology but also as a top employer committed to fostering a workplace where innovation and employee well-being are paramount.

For more information about OXB and their impact on gene and cell therapy, please visit www.oxb.com

About OXB

OXB (LSE:OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.